Research consistently demonstrates the superior performance of PSMA-targeted imaging agents compared to other molecular tracers, such as fluoride, fluciclovine, and choline, particularly in patients with biochemical recurrence of prostate cancer. The gene discussed is FOLH1; the disease is prostate cancer.